Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add filters








Language
Year range
1.
Chinese Journal of Primary Medicine and Pharmacy ; (12): 797-800, 2022.
Article in Chinese | WPRIM | ID: wpr-931693

ABSTRACT

Gastroesophageal reflux disease is a series of intraesophageal and/or extraesophageal symptoms caused by the reflux of gastric contents into the esophagus because of abnormal structure and function of gastroesophageal junction. Acid suppression therapy is the preferred treatment, but most patients with gastroesophageal reflux disease have poor symptom control or excessive dose for drug control, resulting in low quality of life. With the renewal of endoscopic equipment, endoscopic adjuvant therapy is attracting the attention of clinical physicians and patients owing to minimal trauma, rapid recovery, obvious symptom control, and few complications. This paper reviews endoscopic adjuvant therapy.

2.
Chinese Journal of Primary Medicine and Pharmacy ; (12): 1662-1664, 2020.
Article in Chinese | WPRIM | ID: wpr-866485

ABSTRACT

Gastroparesis is a neuromuscular disease characterized by nausea and vomiting, early postprandial satiety, abdominal pain and distention.Drug therapy mainly includes gastric motility drugs such as metoclopramide and domperidone.Most patients responded well to drugs in the early stage, and some patients developed severe drug-resistant symptoms.Based on the pathogenesis of gastroparesis and the development of endoscopy technology, the current treatment methods for drug-refractory gastroparesis include gastric electrical stimulation, botulinum toxin injection, pyloric stent, gastric per-oral endoscopic pyloromyotomy, etc.This article will briefly describe the endoscopy-assisted treatment of gastroparesis.

3.
Chinese Journal of Thoracic and Cardiovascular Surgery ; (12): 91-94, 2017.
Article in Chinese | WPRIM | ID: wpr-513313

ABSTRACT

Objective This study was to analyze the early and long-term effect of completion pneumonectomy.Methods Retrospective analysis was made on the patients who underwent completion pneummonectomy in Shanghai Chest Hospital.Results There were totally 56 cases patients underwent completion pneumonectomy during January 2003 to July 2013.Among them,45 patients received CCP,and other 11 patients received RCP.CCP refers to the complete removal of lung tissue remaining after an initial ipsilateral partial pulmonary resection.RCP refers to the complete removal of residual lung due to the severe complications after pneumonectomy.The mortality and morbidity rate of CCP were 4.4% and 33.3% respectively.In the case of CCP,the incidence of benign lesions is significantly higher than the incidence of malignant tumor(80.0% vs 27.5%,P =0.04).The mortality and morbidity rate of RCP were 27.3% and 90.9% respectively.In the case of RCP,higher postoperative mortality often occurs in aged patients (P =0.046) and patients with preoperatie mechanical ventilation (P =0.03).Overall five-year survival rate for patients with benign lesions was 80%,and for malignant lung cancer patients,the number was 30%.Survival time differs according to the TNM staging(a median of 60.0 months,35.0 months,10.0 months,stage Ⅰ,stage Ⅱ,stage Ⅲ,P <0.01),and survival rate was higher when the time interval(between the initial pulmonary resection and the completion pneumonectomy) > 2 years(a median of 60.0 months,18.0 months,P < 0.01).Conclusion Completion pneumonectomy is a high-risk surgery,especially RCP.Advanced age and preoperative mechanical ventilation are associated with higher postoperative mortality rate for RCP.As for CCP,higher postoperative risk exists in patients with benign lesions,but the survival rate is also higher.In patients with malignant lung tumor,survival rate is higher when the time interval (between the initial pulmonary resection and the completion pneumonectomy) >2 year.

4.
International Journal of Laboratory Medicine ; (12): 510-512, 2015.
Article in Chinese | WPRIM | ID: wpr-462180

ABSTRACT

Objective To evaluate the relationship and bias of the Stago-CT and CA1500 automatic coagulation analyzer.Meth-ods The relationship and bias of PT,APTT,INR,FIB,TT,DD examined by the Stago-CT and CA1500 automatic coagulation ana-lyzer by using NCCLS EP9-A2.Results For the six items(PT,APTT,INR,FIB,TT,DD)the r2 were 0.996 9,0.969 1,0.967 7, 0.955 8,0.972 6,0.949 6,respectively,and the bias were 2.9,0.88,5.22,1.16,3.48,20.3.Conclusion The five items (PT, APTT,INR,FIB,TT)at a good relationship(r2 >0.95)by the Stago-CT and CA1500 automatic coagulation analyzer except for the DD(r2 =0.949 6);The bias of the five items(PT,APTT,INR,FIB,TT)were within in the United States of demanding that a third of the clinical laboratory of CLIA 88′bias,except for the DD.

5.
China Pharmacist ; (12): 293-295, 2014.
Article in Chinese | WPRIM | ID: wpr-452761

ABSTRACT

Objective:To explore the drug application in the postoperative chemotherapy for the patients with non-small cell lung cancer. Methods:The chemotherapy regimens, drug utilization and adverse drug reactions in the non-small cell lung cancer patients received postoperative chemotherapy in 2012 were statistically analyzed in a retrospective study. Results:Totally 8 kinds of chemother-apy regimens were used in 156 cases. The NC( vinorelbine + carboplatin) regimen was used most frequently and the PC( pemetrexed+ carboplatin) regimen was with the highest expense. Proton pump inhibitors, recombinant human erythropoietin and lentinan were the top three in the adjuvant drugs used in the treatment. Conclusion:It is necessary to further standardize the postoperative chemo-therapy for non-small cell lung cancer patients. Thoracic surgeons along with pharmacists should strengthen the drug use monitoring during the whole treatment process to promote the rational drug use.

6.
Chinese Journal of Tissue Engineering Research ; (53): 5929-5935, 2013.
Article in Chinese | WPRIM | ID: wpr-437436

ABSTRACT

BACKGROUND: Chinese medicine Gukang prescription has a clear effect on clinical treatment of osteoporosis, but the therapeutic pathway is stil unclear. OBJECTIVE:To investigate the effects of Chinese medicine Gukang on the expression of receptor activator of nuclear factor kappa B ligand and osteoprotegerin by regulating core binding factor alpha 1 expression to control the growth and development of osteoblasts. METHODS:Sprague-Dawley neonatal rats within 24 hours after delivery were used for the separation and culture of osteoblasts. Adult Sprague-Dawley rats were used to prepare drug-containing serum, and then divided into two groups randomly:normal control group and Gukang group. Rats in the normal control and Gukang groups were intragastrical y administrated with extract of Gukang prescription and normal saline based on rat’s body surface area, for 1 consecutive week. Two hours after the last administration, blood samples were taken from the heart. Then the serum was col ected. Osteoblasts at passage 3 were confirmed with alkaline phosphatase assay and digested. After counting and planting, al osteoblasts were divided into two groups and treated with col ected serum for 72 hours. Proliferative rate of osteoblasts was detected by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test. Secretion of alkaline phosphatase was detected by using enzyme linked immunosorbent assay and corrected with the corresponding absorbance value. mRNA expression of core binding factor alpha 1, receptor activator of nuclear factor kappa B ligand and osteoprotegerin were detected by using reverse transcription-PCR in al groups. RESULTS AND CONCLUSION:mRNA expression of osteoprotegerin and core binding factor alpha 1 in the Gukang group was significantly higher than that in the normal control group, but protein and mRNA expression of receptor activator of nuclear factor kappa B ligand were dramatical y lower in the Gukang group compared with the normal control group (Pcore binding factor alpha 1, thereby adjusting the expression of receptor activator of nuclear factor kappa B ligand and osteoprotegerin, which may be one of the mechanisms underlying Gukang treatment for osteoporosis.

SELECTION OF CITATIONS
SEARCH DETAIL